How to Verify a Peptide COA: Report Authenticity, Batch Traceability, Purity and Content

Notice: For laboratory research and analytical evaluation only. Not for human, veterinary, or clinical use. This article provides technical guidance on reviewing analytical certificates and laboratory reports for B2B research peptide procurement.

Quick answer: A Certificate of Analysis (COA) or third-party analytical report summarizes test results for specific parameters; it does not, on its own, constitute an unbroken chain of custody. Analytical review requires evaluating four distinct dimensions:

1. Report Source and Authenticity: Verifying who generated the document (internal quality control vs. independent third-party laboratory) and whether the document can be compared directly with the issuing facility's records.
2. Sample-to-Batch Traceability: Ensuring the tested sample correlates directly with the specific commercial lot through formal batch records, consistent identifiers, and verified physical presentation.
3. Measurand and Labeling Basis: Distinguishing chromatographic purity (relative peak area percent) from target-peptide assay and net peptide content, and confirming whether nominal vial labels reflect target peptide quantity or gross powder mass.
4. Methodological Scope and Limitations: Recognizing what the analytical technique can and cannot confirm (e.g., intact mass consistency vs. full sequence confirmation; elemental quantification vs. chemical speciation; single-vial measurement vs. batch-wide uniformity).

1. Core Distinctions in Peptide Analytics

Evaluating documentation requires understanding fundamental distinctions established in analytical peptide chemistry (for technical definitions, see Bachem's Peptide FAQ and Knowledge Center and Quality Control Guide):

Chromatographic Purity vs. Net Peptide Content vs. Target-Peptide Assay

• HPLC Area Purity (%): Measures the relative peak area of the principal peak compared to total detected peaks absorbing under the specified chromatographic conditions (typically UV at 214–220 nm). It does not quantify non-absorbing substances (counterions, inorganic salts, water) or establish absolute mass.
• Net Peptide Content (NPC, %): Represents the percentage of peptide-related material relative to the total mass of the powder, accounting for non-peptide components like moisture and counterions. NPC reflects total peptidic mass and may include closely related peptide impurities; non-specific assays like elemental nitrogen determination do not distinguish the target sequence from other nitrogenous peptide fragments.
• Target-Peptide Assay (mg per vial): Measures the absolute quantity of the specific intact target peptide in a container, determined by a suitable quantitative procedure (such as quantitative HPLC calibrated against a qualified, characterized reference standard). Area normalization alone cannot determine milligrams per vial.

Target Identification vs. Sequence Verification

• Target Identification (Intact Molecular Mass): Intact-mass mass spectrometry (such as ESI-MS) supports consistency with the expected molecular mass based on observed ions (e.g., [M+H]+ and multi-charge envelopes), but does not independently establish the complete sequence or stereochemistry.
• Sequence-Related Evidence: Techniques like MS/MS fragmentation and peptide mapping can provide sequence-related evidence, subject to method coverage and resolving capability. Amino acid analysis (AAA) provides composition and total content information rather than sequence order; stereochemical confirmation requires suitable dedicated chiral methods.

2. Reviewing Third-Party Analytical Reports: Three Real-World Cases

In September–October 2026, finished lyophilized vials labeled under WUMO Peptide batch codes were submitted to Janoshik Analytical (an independent third-party analytical laboratory) for testing.

The table below summarizes the reported findings:

Note: On third-party test certificates, client designation (WUMO Peptide), stated web domain (https://peptide.wumolab.com/), and sample lot identifiers reflect information as supplied by the submitter.

Case 1: Retatrutide 30mg (Task #229086)

• Test Request: The report names the requested service as “Common GLP-1 peptide blind test (Semaglutide, Tirzepatide and Retatrutide).” Details of blinding and analytical procedures should be confirmed with the laboratory where relevant.
• Analytical Findings:
  • Identified: Retatrutide
  • Reported Quantity: 30.68 mg
  • Reported Purity: 99.921%
  • Dates Stated on Report: Testing ordered 31 Aug '26; Sample received 30 Sep '26; Analysis conducted 02 Oct '26
  • Verification: Visit the Janoshik verification portal and enter Task Number 229086 with Unique Key JQ9TVW86S944 to compare the issuing laboratory’s record with the supplied report.
• Data Interpretation and Boundaries:
  • The reported amount for the tested sample was 30.68 mg, equivalent to 102.27% of the nominal 30 mg label claim.
  • This result reports an estimate of the analyte quantity in the submitted sample under the laboratory's method. This result alone does not establish batch-wide fill uniformity or explain the manufacturing process. Establishing consistency across a commercial batch requires documented in-process fill control and release testing across multiple sampled containers.

Case 2: GHK-Cu 50mg (Task #229087)

• Test Request: GHK (or GHK-Cu) analysis.
• Analytical Findings:
  • Reported Purity: 99.948%
  • Reported Quantitative Values: GHK-Cu (GHK content) [Copper Content]: 48.31 mg (41.06 mg) [7.25 mg]
  • Dates Stated on Report: Testing ordered 31 Aug '26; Sample received 30 Sep '26; Analysis conducted 02 Oct '26
  • Verification: Visit the Janoshik verification portal and enter Task Number 229087 with Unique Key H6VDSKWM52MV to compare the issuing laboratory’s record with the supplied report.
• Data Interpretation and Boundaries:
  • The report lists GHK and copper values separately. Interpretation of the combined figure requires clarification of the laboratory's reporting basis and calculation method. These values alone do not establish copper speciation or the absence of uncomplexed copper.
  • Evaluating whether a sample meets procurement requirements requires reference to pre-agreed specifications rather than generalized assumptions regarding salt form or fill variance. Specifications, moisture limits, and acceptable tolerances should be defined explicitly in written quality agreements.

Case 3: MOTS-c 10mg (Task #229088)

• Test Request: MOTS-c analysis.
• Analytical Findings:
  • Reported Quantity: 10.76 mg
  • Reported Purity: 98.382%
  • Dates Stated on Report: Testing ordered 31 Aug '26; Sample received 30 Sep '26; Analysis conducted 02 Oct '26
  • Verification: Visit the Janoshik verification portal and enter Task Number 229088 with Unique Key ZQTGUWI27RZX to compare the issuing laboratory’s record with the supplied report.
• Data Interpretation and Boundaries:
  • The measured mass of 10.76 mg indicates the quantity measured in the submitted vial under the laboratory's procedure. If the reported purity is based on chromatographic area normalization, the complementary 1.618% represents non-main-peak area under that method, rather than an established impurity mass fraction.
  • An analyte quantity exceeding the nominal label claim does not offset or resolve the presence of chromatographic impurities, and high purity does not compensate for an under-filled container. Purity and quantity must each be evaluated independently against customer-defined specifications.

3. What Independent Testing Reports Do Not Establish

Technical procurement teams must recognize what analytical test reports on submitted containers do and do not substantiate:

1. Single Container vs. Entire Batch: A test certificate provides analytical data solely for the specific container evaluated by the laboratory. Assessing batch representativeness requires a documented sampling plan appropriate to the lot and the attribute being evaluated, together with results from multiple sampled units. Independent sampling may strengthen confidence in sample selection and traceability.
2. Untested Safety and Quality Parameters: A certificate reporting identity, chromatographic purity, and peptide quantity does not substantiate parameters that were not analyzed, such as:
   • Microbial burden and sterility
   • Bacterial endotoxins
   • Residual solvents
   • Elemental impurities
   • Counterion content
   • Residual moisture
3. No Clinical or In Vivo Suitability: Analytical reports for research peptides evaluate chemical properties for laboratory research use only. They provide no evaluation of biological activity, pharmacokinetic profiles, or suitability for clinical or animal use.
4. Third-Party Role: Laboratory verification portals enable comparison of the supplied document with the issuing laboratory's records, confirming that the digital record matches what the laboratory released. They do not certify the commercial legitimacy of a vendor or verify chain of custody once goods are delivered.

4. How to Verify a Third-Party Report

When auditing documentation provided by a supplier, execute the following three-step verification procedure:

[1. Independent Record Comparison] ---> [2. Batch & Physical Alignment] ---> [3. Method & Chromatographic Review]

Step 1: Query the Independent Verification Portal

Never rely solely on an unverified PDF copy.

• Locate the official verification endpoint designated by the issuing facility (for Janoshik reports, visit https://janoshik.com/verification/).
• Enter both the Task Number (e.g., 229086) and the Unique Key (e.g., JQ9TVW86S944).
• Confirm that the returned record matches the task number, client name, sample designation, batch identifier, and analytical values.

Step 2: Correlate Identifiers with Consignment Records

• Confirm that the batch code stated on the test report corresponds with the code on commercial shipping invoices, packing lists, and vial labels.
• Examine intake photographs provided in the report to ensure container format (crimp seal color, vial dimensions, label presentation) aligns with delivered goods.
• Note that client name and batch codes on third-party reports typically reflect information as supplied by the submitter; verify that internal production or compounding records link the bulk synthesis lot to that fill batch.

Step 3: Review Method Parameters and Chromatograms

When analytical data packs are evaluated:

• Chromatographic Conditions: Review the column type, mobile phase composition, gradient slope, flow rate, and detection wavelength (e.g., UV 214–220 nm).
• Peak Integration: Inspect baseline integration across the chromatogram. Ensure integration rules are applied consistently and that separation between the main target peak and adjacent minor peaks is documented.
• Reporting Limitations: Note that non-chromophoric formulation bulking agents (such as mannitol or trehalose) and inorganic salts are generally not reliably evaluated by standard reverse-phase HPLC-UV purity methods; evaluating these excipients requires dedicated analytical procedures (such as CAD, RI, or IC).

5. Technical Parameters to Agree Before Ordering

To prevent commercial disputes, the following parameters should be agreed upon in writing — within the product specification sheet, quality agreement, or commercial terms — prior to payment:

6. Sourcing & Technical Documentation Support

For a proposed order, ask WUMO Peptide to confirm the documentation available for the relevant lot, including any supplier COA and third-party report. The applicable specifications, sampling arrangements and any additional testing should be agreed before order confirmation.

For laboratory research use only. Not for human or veterinary use.